{"id":"https://openalex.org/W2107485485","doi":"https://doi.org/10.1158/1078-0432.ccr-13-1637","title":"Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy","display_name":"Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy","alternate_titles":[],"publication_year":2013,"publication_date":"2013-09-12","ids":{"openalex":"https://openalex.org/W2107485485","doi":"https://doi.org/10.1158/1078-0432.ccr-13-1637","mag":"2107485485","pmid":"https://pubmed.ncbi.nlm.nih.gov/24030704"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-13-1637","doi":"https://doi.org/10.1158/1078-0432.ccr-13-1637","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-13-1637","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2107485485"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027141514","display_name":"Neil R. Smith","orcid":"https://orcid.org/0000-0002-0023-4398","observed_orcids":["https://orcid.org/0000-0002-0023-4398"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I84884186","display_name":"Newcastle University","ror":"https://ror.org/01kj2bm70","country_code":"GB","type":"education","lineage":["https://openalex.org/I84884186"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Neil R. Smith","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I84884186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072961963","display_name":"Dawn Baker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I84884186","display_name":"Newcastle University","ror":"https://ror.org/01kj2bm70","country_code":"GB","type":"education","lineage":["https://openalex.org/I84884186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Dawn Baker","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I84884186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036794959","display_name":"Matthew R. Farren","orcid":"https://orcid.org/0000-0001-5510-8869","observed_orcids":["https://orcid.org/0000-0001-5510-8869"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I84884186","display_name":"Newcastle University","ror":"https://ror.org/01kj2bm70","country_code":"GB","type":"education","lineage":["https://openalex.org/I84884186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Matthew Farren","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I84884186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043679506","display_name":"Aur\u00e9lien Pommier","orcid":"https://orcid.org/0009-0001-6540-1863","observed_orcids":["https://orcid.org/0009-0001-6540-1863"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I84884186","display_name":"Newcastle University","ror":"https://ror.org/01kj2bm70","country_code":"GB","type":"education","lineage":["https://openalex.org/I84884186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Aurelien Pommier","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I84884186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075788359","display_name":"Ruth Swann","orcid":"https://orcid.org/0000-0003-3789-4979","observed_orcids":["https://orcid.org/0000-0003-3789-4979"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I84884186","display_name":"Newcastle University","ror":"https://ror.org/01kj2bm70","country_code":"GB","type":"education","lineage":["https://openalex.org/I84884186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ruth Swann","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I84884186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100328079","display_name":"Xin Wang","orcid":"https://orcid.org/0000-0003-1443-7732","observed_orcids":["https://orcid.org/0000-0003-1443-7732"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I84884186","display_name":"Newcastle University","ror":"https://ror.org/01kj2bm70","country_code":"GB","type":"education","lineage":["https://openalex.org/I84884186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Xin Wang","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I84884186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041837205","display_name":"Sunita Mistry","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I84884186","display_name":"Newcastle University","ror":"https://ror.org/01kj2bm70","country_code":"GB","type":"education","lineage":["https://openalex.org/I84884186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sunita Mistry","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I84884186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014495669","display_name":"Karen McDaid","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I84884186","display_name":"Newcastle University","ror":"https://ror.org/01kj2bm70","country_code":"GB","type":"education","lineage":["https://openalex.org/I84884186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Karen McDaid","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I84884186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001053254","display_name":"Jane Kendrew","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I84884186","display_name":"Newcastle University","ror":"https://ror.org/01kj2bm70","country_code":"GB","type":"education","lineage":["https://openalex.org/I84884186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jane Kendrew","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I84884186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088879446","display_name":"Chris Womack","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I84884186","display_name":"Newcastle University","ror":"https://ror.org/01kj2bm70","country_code":"GB","type":"education","lineage":["https://openalex.org/I84884186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Chris Womack","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I84884186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058765817","display_name":"Stephen R. Wedge","orcid":"https://orcid.org/0000-0002-3644-6157","observed_orcids":["https://orcid.org/0000-0002-3644-6157"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I84884186","display_name":"Newcastle University","ror":"https://ror.org/01kj2bm70","country_code":"GB","type":"education","lineage":["https://openalex.org/I84884186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Stephen R. Wedge","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I84884186"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044054725","display_name":"Simon T. Barry","orcid":"https://orcid.org/0000-0002-8511-0588","observed_orcids":["https://orcid.org/0000-0002-8511-0588"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I84884186","display_name":"Newcastle University","ror":"https://ror.org/01kj2bm70","country_code":"GB","type":"education","lineage":["https://openalex.org/I84884186"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Simon T. Barry","raw_affiliation_strings":["Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire; and 2Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom","institution_ids":["https://openalex.org/I105036370","https://openalex.org/I84884186"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5027141514","https://openalex.org/A5044054725"],"corresponding_institution_ids":["https://openalex.org/I105036370","https://openalex.org/I84884186"],"apc_list":null,"apc_paid":null,"fwci":4.4492,"has_fulltext":false,"cited_by_count":149,"citation_normalized_percentile":{"value":0.96488111,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":100},"biblio":{"volume":"19","issue":"24","first_page":"6943","last_page":"6956"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11469","display_name":"Lymphatic System and Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10336","display_name":"Cancer Cells and Metastasis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vegf-inhibitors","display_name":"VEGF inhibitors","score":0.8600000143051147},{"id":"https://openalex.org/keywords/vegfr2","display_name":"VEGFR2","score":0.7680000066757202},{"id":"https://openalex.org/keywords/dc101","display_name":"DC101","score":0.8640000224113464},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9319999814033508},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.8190000057220459},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.9240000247955322},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9070000052452087},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.6800000071525574},{"id":"https://openalex.org/keywords/cd31","display_name":"CD31","score":0.7649999856948853},{"id":"https://openalex.org/keywords/alpha-smooth-muscle-actin","display_name":"alpha-smooth muscle actin","score":0.9190000295639038},{"id":"https://openalex.org/keywords/vascular-structure","display_name":"vascular architecture","score":0.3140000104904175}],"concepts":[{"id":"https://openalex.org/C16930146","wikidata":"https://www.wikidata.org/wiki/Q4381253","display_name":"Stromal cell","level":2,"score":0.735741376876831},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.5870754718780518},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5320613980293274},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.5065428018569946},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.49742892384529114},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.49720361828804016},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.46510040760040283},{"id":"https://openalex.org/C52124034","wikidata":"https://www.wikidata.org/wiki/Q557179","display_name":"Stroma","level":3,"score":0.4546840190887451},{"id":"https://openalex.org/C2778939058","wikidata":"https://www.wikidata.org/wiki/Q4046167","display_name":"CD31","level":3,"score":0.41700249910354614},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.32147374749183655},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.25507867336273193},{"id":"https://openalex.org/C204232928","wikidata":"https://www.wikidata.org/wiki/Q899285","display_name":"Immunohistochemistry","level":2,"score":0.2290148138999939},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.21162453293800354}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000199","descriptor_name":"Actins","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D009389","descriptor_name":"Neovascularization, Pathologic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009389","descriptor_name":"Neovascularization, Pathologic","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D017154","descriptor_name":"Stromal Cells","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D017154","descriptor_name":"Stromal Cells","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D019408","descriptor_name":"Platelet Endothelial Cell Adhesion Molecule-1","qualifier_ui":"Q000096","qualifier_name":"biosynthesis","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D040301","descriptor_name":"Vascular Endothelial Growth Factor Receptor-2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D040301","descriptor_name":"Vascular Endothelial Growth Factor Receptor-2","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.ccr-13-1637","doi":"https://doi.org/10.1158/1078-0432.ccr-13-1637","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-13-1637","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:24030704","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24030704","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":33,"referenced_works":["https://openalex.org/W1756949381","https://openalex.org/W1970107343","https://openalex.org/W1977999028","https://openalex.org/W1979591854","https://openalex.org/W1997062296","https://openalex.org/W1997596656","https://openalex.org/W2017322644","https://openalex.org/W2020239598","https://openalex.org/W2021777913","https://openalex.org/W2026734453","https://openalex.org/W2026996188","https://openalex.org/W2031563027","https://openalex.org/W2063249586","https://openalex.org/W2068562114","https://openalex.org/W2069079717","https://openalex.org/W2071185061","https://openalex.org/W2081887573","https://openalex.org/W2096415778","https://openalex.org/W2097373408","https://openalex.org/W2103928688","https://openalex.org/W2106805175","https://openalex.org/W2115068822","https://openalex.org/W2126163864","https://openalex.org/W2128095147","https://openalex.org/W2131475943","https://openalex.org/W2132697290","https://openalex.org/W2133354058","https://openalex.org/W2137508065","https://openalex.org/W2139731402","https://openalex.org/W2156835104","https://openalex.org/W2158474413","https://openalex.org/W2162424705","https://openalex.org/W6637994761"],"related_works":["https://openalex.org/W2015503105","https://openalex.org/W2069326446","https://openalex.org/W1955926845","https://openalex.org/W7220941672","https://openalex.org/W2171228060","https://openalex.org/W1988887021","https://openalex.org/W2111452613","https://openalex.org/W2071185061","https://openalex.org/W1970107343","https://openalex.org/W2047164016"],"abstract_inverted_index":{"PURPOSE:":[0],"The":[1,44,176,204],"aim":[2],"of":[3,14,37,48,68,131,141,149],"the":[4,9,77,100,129,139,155,169,228],"study":[5],"was":[6,180],"to":[7,28,31,76,89,164,194,216,226,245,253],"investigate":[8],"vascular":[10],"and":[11,18,40,50,60],"stromal":[12,156,170,206],"architecture":[13,47,207],"preclinical":[15,49,239],"tumor":[16,20,45,52,83,101,132,151,177,205,212,248],"models":[17,66,153,161,172],"patient":[19],"specimens":[21],"from":[22],"malignancies":[23,111],"with":[24,85,183,231,250],"known":[25],"clinical":[26,51,229],"outcomes":[27],"VEGFi":[29,255],"treatment,":[30],"gain":[32],"insight":[33],"into":[34],"potential":[35],"determinants":[36],"intrinsic":[38,251],"sensitivity":[39,75,252],"resistance.":[41],"EXPERIMENTAL":[42],"DESIGN:":[43],"stroma":[46,135],"samples":[53],"were":[54,71,162,173],"analyzed":[55],"by":[56],"staining":[57],"for":[58,74],"CD31":[59],"\u03b1-smooth":[61],"muscle":[62],"actin":[63],"(\u03b1-SMA).":[64],"Tumor":[65,159],"representative":[67],"each":[69],"phenotype":[70,179],"then":[72],"tested":[73],"VEGFR2-blocking":[78,165],"antibody":[79,166],"DC101.":[80],"RESULTS:":[81],"Human":[82],"types":[84,213,249],"high":[86],"response":[87,193],"rates":[88],"VEGF":[90,218],"inhibitors":[91],"(e.g.,":[92],"renal":[93],"cell":[94,120],"carcinoma)":[95],"have":[96],"vessels":[97,142],"distributed":[98],"amongst":[99],"cells":[102,133],"(a":[103,143],"\"tumor":[104],"vessel\"":[105,145],"phenotype,":[106],"TV).":[107],"In":[108,224],"contrast,":[109],"those":[110],"where":[112],"single-agent":[113,222],"responses":[114],"are":[115],"lower,":[116],"such":[117],"as":[118,221],"non-small":[119],"lung":[121],"cancer":[122,201],"(NSCLC),":[123],"display":[124],"a":[125,184,217,254],"complex":[126],"morphology":[127],"involving":[128],"encapsulation":[130],"within":[134],"that":[136,214],"also":[137,181],"supports":[138],"majority":[140],"\"stromal":[144],"phenotype).":[146],"Only":[147],"1":[148],"31":[150],"xenograft":[152],"displayed":[154],"vessel":[157,160,171,178],"phenotype.":[158],"sensitive":[163],"DC101,":[167],"whereas":[168],"exclusively":[174],"refractory.":[175],"associated":[182],"better":[185],"Response":[186],"Evaluation":[187],"Criteria":[188],"in":[189,198,238],"Solid":[190],"Tumors":[191],"(RECIST)":[192],"bevacizumab":[195],"+":[196],"chemotherapy":[197],"metastatic":[199],"colorectal":[200],"(CRC).":[202],"CONCLUSION:":[203],"can":[208],"differentiate":[209],"between":[210],"human":[211],"respond":[215],"signaling":[219],"inhibitor":[220],"therapy.":[223],"addition":[225],"reconciling":[227],"experience":[230],"these":[232,241],"agents":[233],"versus":[234],"their":[235],"broad":[236],"activity":[237],"models,":[240],"findings":[242],"may":[243],"help":[244],"select":[246],"solid":[247],"or":[256],"other":[257],"vascular-directed":[258],"therapies.":[259]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2107485485","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":17},{"year":2019,"cited_by_count":15},{"year":2018,"cited_by_count":16},{"year":2017,"cited_by_count":15},{"year":2016,"cited_by_count":14},{"year":2015,"cited_by_count":17},{"year":2014,"cited_by_count":16},{"year":2013,"cited_by_count":3}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2016-06-24T00:00:00"}
